Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
- 15 July 2019
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (10), 686-688
- https://doi.org/10.1016/j.clml.2019.07.003
Abstract
No abstract availableKeywords
Funding Information
- Takeda Millennium
- Janssen
- Prothena
- AbbVie
- Karyopharm
- Sanofi
This publication has 4 references indexed in Scilit:
- Use of novel therapies in the treatment of light chain amyloidosisBlood Reviews, 2019
- Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaBlood, 2017
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMBlood, 2017
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyPublished by American Society of Hematology ,2005